Epitranscriptic regulation of HRAS by N⁶-methyladenosine drives tumor progression

Area of Science:

• Molecular Biology
• Oncology
• Epigenetics

Background:

• Ras proteins are frequently overexpressed or mutated in human cancers.
• Mechanisms of epitranscriptic regulation of RAS in tumorigenesis are not fully understood.

Purpose of the Study:

• To investigate the role of N6-methyladenosine (m6A) modification in RAS gene regulation during cancer development.
• To elucidate the specific RAS isoforms and regulatory pathways involved.

Main Methods:

• Analysis of m6A modification levels in HRAS, KRAS, and NRAS in cancer versus adjacent tissues.
• Investigating the impact of m6A modification on H-Ras protein expression and function.
• Identifying m6A regulators (FTO, YTHDF1/2/3) and their binding sites on HRAS mRNA.
• Assessing the effect of targeting HRAS m6A modification on cancer cell proliferation and metastasis.
• Correlating H-Ras, FTO, and YTHDF1 expression in clinical cancer samples.

Main Results:

• Widespread m6A modification of HRAS, but not KRAS or NRAS, was elevated in cancer tissues.
• m6A modification of HRAS promotes H-Ras protein expression via enhanced translational elongation.
• Specific m6A sites in the HRAS 3' UTR, regulated by FTO and bound by YTHDF1, enhance translation.
• Targeting HRAS m6A modification reduced cancer proliferation and metastasis.
• Clinical data showed inverse correlation between FTO and H-Ras, and positive correlation between YTHDF1 and H-Ras.

Conclusions:

• Specific m6A modification sites in HRAS play a crucial role in promoting cancer cell proliferation and metastasis.
• The FTO/YTHDF1 axis regulates HRAS m6A modification to drive tumorigenesis.
• Targeting HRAS m6A modification represents a potential therapeutic strategy for Ras-driven cancers.